Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Addressing, AGAVE, aimed, ALLG, Antitrust, argued, artifice, ASR, Australian, axatilmab, azacytidine, batch, Beat, behavior, belomosidil, booking, clonal, convey, COSO, CR, custody, daily, decency, Delinquent, Deloitte, deployed, digit, dignity, discrimination, dismissed, Division, double, drawn, drew, EGC, enzyme, EP, ethnicity, evolution, excercise, falsifying, fascia, Fast, float, fourteen, frontline, fulfill, gauge, gender, gradually, graph, greatest, handbook, harassment, Head, Huber, ID, idiopathic, index, induction, infection, instructed, INTERCEPT, intervened, IPF, learning, liver, LLP, Lymphoma, macroeconomic, Martin, Master, mathematical, MD, methodology, MFN, obstructing, ODD, offense, ORR, outlined, paramount, pertain, post, PPACA, Presidential, principle, pulmonary, QT, race, reactivation, reevaluate, refund, reinvested, remit, residual, retroactive, Rezurock, robust, rollforward, rollout, settle, shareholder, simultaneously, SRL, sum, susceptible, timeline, Touche, trick, unasserted, undistributed, unexpired, unqualified, unwind, unwound, vaccination, venetoclax, vii, viral, workplace
Removed:
activate, Africa, AstraZeneca, attack, attractive, Australia, BBA, Bipartisan, blood, Brazil, calendar, cellular, checkpoint, close, cohort, compute, concept, conference, consolidation, cooperate, cytotoxic, deducting, district, donut, effected, EPO, evade, exceeded, explanation, expressing, Fabrice, fall, Hakko, hereof, hole, Imfinzi, immunosensitivity, immunosuppressive, immunotherapy, indefinitely, intercompany, irrevocably, issuable, Judge, Jumpstart, killing, latitude, lend, leveraging, localize, long, Mexico, microenvironment, modulate, monthly, MPM, omit, opened, parallel, permissible, permitting, pharmacodynamic, pharmacokinetic, PharmD, profound, proof, purpose, recurring, regression, requesting, resistance, resistant, revised, South, SPA, sparing, studied, suppressor, synergistically, transition, tumor, unaudited, undergoing, undetected, updated, weekly, writing
Filing tables
Filing exhibits
Related press release
Associated SNDX transcripts
SNDX similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement No. 333-254661 on Form S-3 and Registration Statement Nos. 333-210412, 333-220172, 333-226678, 333-233083, 333-241654, and 333-258628 on Form S-8 of our reports dated March 1, 2022, relating to the financial statements of Syndax Pharmaceuticals, Inc. and subsidiaries and the effectiveness of Syndax Pharmaceuticals, Inc. and subsidiaries’ internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 1, 2022